Insmed Inc. (INSM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insmed Inc. (INSM)

INSM 189.58

-2.4%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	12/16/2003 2:50:39 AM
	Read Replies (1) of 136

INSM US: INSM Gets Orphan Drug Designation for SomatoKine 2003-12-15 13:47 (New York) INSMED INC ("INSM-Q") - INSM Gets Orphan Drug Designation for SomatoKine Insmed Incorporated (INSM) announced that the Office of Orphan Products Development of FDA has approved the Company's application for orphan drug designation in the US for SomatoKine(R), for the treatment of extreme insulin resistance. With this orphan drug designation, Insmed will be granted seven years of market exclusivity upon SomatoKine(R) approval for this indication. There is currently no approved treatment available for patients with extreme insulin resistance in the US.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next